Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mathieu Molimard

Showing results (161-170 of 170) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 170 results.
European Journal of Cancer (Oxford, England : 1990)|February 7, 2016
Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life settingStéphane Bouchet, Sylvie Poulette, Karine Titier, et al.
BMJ Open|July 3, 2020
Prioritising outcomes for evaluating eosinophil-guided corticosteroid therapy among patients with acute COPD exacerbations requiring hospitalisation: a Delphi consensus studyCarey Meredith Suehs, Maéva Zysman, Cécile Chenivesse, et al.
European Journal of Cancer (Oxford, England : 1990)|September 9, 2017
Phase I study of axitinib and everolimus in metastatic solid tumours and extension to metastatic renal cell carcinoma: Results of EVAX studyAlain Ravaud, Carlos Gomez-Roca, Marie-Quitterie Picat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2010
Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinibDavid Marin, Alexandra Bazeos, Francois-Xavier Mahon, et al.
Therapie|August 8, 2014
Information and communication on risks related to medications and proper use of medications for healthcare professionals and the general public: precautionary principle, risk management, communication during and in the absence of crisis situationsMathieu Molimard, Corine Bernaud, Philippe Lechat, et al.
Therapie|July 10, 2016
[Not Available]Mathieu Molimard, Corine Bernaud, Philippe Lechat, et al.
Fundamental & Clinical Pharmacology|May 13, 2020
Genesis of an emergency public drug information website by the French Society of Pharmacology and Therapeutics during the COVID-19 pandemicLouis Larrouquere, Manon Gabin, Emmanuelle Poingt, et al.
British Journal of Haematology|July 1, 2021
Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patientsPhilippe Rousselot, Luigina Mollica, Joëlle Guilhot, et al.
Pharmaceutics|August 26, 2022
Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid LeukemiaHyacinthe Johnson-Ansah, Benjamin Maneglier, Françoise Huguet, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|March 19, 2022
Inhaled ciclesonide for outpatient treatment of COVID-19 in adults at risk of adverse outcomes: a randomised controlled trial (COVERAGE)Alexandre Duvignaud, Edouard Lhomme, Racha Onaisi, et al.
Pageof 17

Showing results (161-170 of 170) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 170 results.
European Journal of Cancer (Oxford, England : 1990)|February 7, 2016
Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life settingStéphane Bouchet, Sylvie Poulette, Karine Titier, et al.
BMJ Open|July 3, 2020
Prioritising outcomes for evaluating eosinophil-guided corticosteroid therapy among patients with acute COPD exacerbations requiring hospitalisation: a Delphi consensus studyCarey Meredith Suehs, Maéva Zysman, Cécile Chenivesse, et al.
European Journal of Cancer (Oxford, England : 1990)|September 9, 2017
Phase I study of axitinib and everolimus in metastatic solid tumours and extension to metastatic renal cell carcinoma: Results of EVAX studyAlain Ravaud, Carlos Gomez-Roca, Marie-Quitterie Picat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2010
Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinibDavid Marin, Alexandra Bazeos, Francois-Xavier Mahon, et al.
Therapie|August 8, 2014
Information and communication on risks related to medications and proper use of medications for healthcare professionals and the general public: precautionary principle, risk management, communication during and in the absence of crisis situationsMathieu Molimard, Corine Bernaud, Philippe Lechat, et al.
Therapie|July 10, 2016
[Not Available]Mathieu Molimard, Corine Bernaud, Philippe Lechat, et al.
Fundamental & Clinical Pharmacology|May 13, 2020
Genesis of an emergency public drug information website by the French Society of Pharmacology and Therapeutics during the COVID-19 pandemicLouis Larrouquere, Manon Gabin, Emmanuelle Poingt, et al.
British Journal of Haematology|July 1, 2021
Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patientsPhilippe Rousselot, Luigina Mollica, Joëlle Guilhot, et al.
Pharmaceutics|August 26, 2022
Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid LeukemiaHyacinthe Johnson-Ansah, Benjamin Maneglier, Françoise Huguet, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|March 19, 2022
Inhaled ciclesonide for outpatient treatment of COVID-19 in adults at risk of adverse outcomes: a randomised controlled trial (COVERAGE)Alexandre Duvignaud, Edouard Lhomme, Racha Onaisi, et al.
Pageof 17